About NeuroGenesis


diagram 4.png

Since the initiation of our Phase I trial in 2005, we are advancing our novel NEURALyzed CELL™ platform to develop, manufacture, and deliver an entirely new generation of cell therapies for neurodegenerative diseases.

Our foundational science harnesses the platform ability to neuralize cells by maximizing their immunomodulation potential, neuronal protection and regenerative capabilities.
We are excited about delivering on the promise of neuralized cellular therapies, shaping the future of cellular medicine, and delivering new therapies to many unmet needs in the neurodegenerative diseases market.

NeuroGenesis will initiate a multi-center Phase III clinical trial (Progressive Multiple Sclerosis) in 2021 as well as a Phase I in ALS (Lou Gehrig’s disease).